1. Gury, C, Canceil, O, Laria, P. Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale. 2000;26:62–72.
2. Reilly, JG, Ayis, SA, Ferrier, IN. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048–1052.
3. Moss, AJ. Measurement of QT ihterval and the risk associated with QTc interval prolongation: a review. Am J Cardiol. 1993;72:238–258.
4. Fayek, M, Kingsbury, SJ, Simpson, GM, Zada, J. Cardiac effects of antipsychotics medications. Psychiatr Serv. 2001;52:607–609.
5. American Psychiatric Association. Sudden Death in Psychiatric Patients: The Role of Neuroleptic Drugs. Task Force Report 27. Washington, DC: American Psychiatric Association; 1987.
6. Faber, TS, Zehender, M, Just, H. Drug-induced torsades de pointes: incidence management and prevention. Drug Saf. 1994;11:463–476.
7. Welch, R, Chue, P. Antipsychotic agents and QT changes. J Psychiatry Neurosci. 2000;25:154–160.
8. Selzer, A, Wray, HW. Quinidine syncope: paroxysmal ventricular fibrillation occur-ring during treatment of chronic atrial arrhythmias. Circulation. 1964;30:17–26.
9. Rodem, DM, Woosley, RL, Primm, R.K.Incidence and clinical features of quinidine associated long QT syndrome: implications for patient care. Am Heart J. 1986;111:1088–1093.
10. Kay, GN, Plumb, VJ, Arciniegas, JG, et al. Torsades de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol. 1983;2:806–817.
11. Bauman, JL, Bauernfeind, RA, Hoff, JV, et al. Torsades de pointes due to quinidine: observations in 31 patients. Am Heart J. 1984;107:425–430.
12. Torp-Pederson, C, Moller, M, Bloch-Thomsen, PE, et al. The Danish investigation of arrhythmia and mortality on dofetilide study group: dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:679–911.
13. Stambler, BS, Wood, MA, Ellen Bogen, KA, et al. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter to fibrillation. Ibutilide Repeat Dose Study Investigators. Circulation. 1996;94:1613–1621.
14. Haverkamp, W, Breithardt, G, Camm, AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmie drugs: clinical and regulatory implications. Eur Heart J. 2000;21:1216–1231
15. Thioridazine HC1 [package insert]. East Hanover. INJ: Novartis Pharmaceuticals Corporation; 2000.
16. Serentil [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2000.
17. Barnett, AA. Safety concerns over antipsychotic drug sertindole. Lancet. 1996;348:256
18. Jann, MW. Clozapine. Pharmacotherapy. 1991;11:179–195.
19. Coward, DM. General pharmacology of clozapine. Br J Psychiatry. 1992;160(suppll7):5–11.
20. Lieberman, JA, Kane, JM, Johns, CA. Clozapine: guidelines for clinical management. J Clin Psychiatry. 1989;50:329–338.
21. Lieberman, JA, Safferman, A. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatric Q. 1992;63:3–14.
22. Marder, SR. Adverse effects of clozapine [monograph]. J Clin Psychiatry. 1996;14:11–12.
23. Gupta, S, Rajaprabhakaran, R. Clozapine-induced hypertension. Am J Psychiatry. 1994;151;148.
24. Jens, G, Kilian, K, Kerr, C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet. 1999;354:1841–1845.
25. Bandelow, B, Degner, D, Kreusch, U, et al. Myocarditis under therapy with clozapine. Schizophr Res. 1995;17:293–294.
26. Leo, RJ, Kreeger, JL, Kim, KY. Cardiomyopalhy associated with clozapine. Ann Pharmacother. 1996;30:603–605.
27. Kang, UG, Kwoon, JS, Ahn, MA, et al. Electrographic abnormalities in patients treated with clozapine. J Clin Psychiatry. 2000:61:441–446.
28. Beale, MD, Pritchett, JT, Kellner, CH. Supraventricular tachycardia in a patient receiving ECT, clozapine, and caffeine. Convuls Ther. 1994;10:228–231.
29. Maynes, D. Bilateral pulmonary embolism in a patient on clozapine therapy. Can J Psychiatry. 2000;45:296–297.
30. Hagg, S, Spigset, O, Soderstrom, TG. Association of venous thromboemholism and clozapine. Lancet. 2000;355:1155–1156.
31. Lacika, S, Cooper, JP. Pulmonary embolus possibly associated with clozapine treatment. Can J Psychiatry. 1999;44:396–397.
32. Ihde-Scholl, T, Rolli, ML, Jefferson, JW. Clozapine and pulmonary embolus. Am J Psychiatry. 2001;158:499–500.
33. Coodin, S, Ballegeer, T. Clozapine therapy and pulmonary embolism. Can J Psychiatry. 2000;45:395.
34. Walker, AM, Lanza, LL, Arellana, F, Rothman, KJ. Mortality in current and former users of clozapine. Epidemiology. 1997;8:671–677.
35. Clardy, J, Gule, RH. Mortality risk and clozapine. Am J Psychiatry. 1995;152:161.
36. Marder, SR, Meibach, RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825–835.
37. Gupta, S, Black, DW, Smith, D. Risperidone: review of its pharmacology, and therapeutic use in schizophrenia. Ann Clin Psychiatry. 1994;6:173–180.
38. Madhusoodanan, S, Brecher, M, Brenner, R, et al. Risperidone in the treatment of elderly patients with psychotic disorders. Amer J Geriatr Psychiatry. 1999;7:132–138.
39. Min, SK, Rhee, CS, Kim, CE, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel-group, double-blind comparative trial. Yonsei Med J. 1997;31:967–870.
40. Hatta, K, Takashashi, T, Nakamura, H, et al. The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharmacol. 2001;21:257–261.
41. Ravin, DS, Levenson, JM. Fatal cardiac event following initiation of risperi-done therapy. Ann Pharmacother. 1997;31:967–870.
42. Chong, SA, Tan, CH, Lee, HS. Atrial ectopics with clozapine-risperidone combination. J Clin Psychopharmacol. 1997;17:130–131.
43. Pfizer, Inc. Study Report of Ziprasidone Clinical Pharmacology Protocol. 2000. Rockville, MD: Food and Drug Administration Center for Drug Evaluation and Research Division of Cardiorenal Drug Products Consultation; 2000.
44. Lemmens, P, Brecher, M, Baelen, BV. Tolerability and cardiovascular safety of risperidone. Acta Psychiatrica Scand. 1999;99:160–170.
45. Gupta, S, Masand, PS. Olanzapine: review of its pharmacology and indications in clinical practice. Primary Psychiatry. 1997;4:73–81.
46. Czekalla, J, Beasley, CM Jr, Dellva, MA, et al. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psychiatry. 2001;62:191–198.
47. Masand, PS, Gupta, S. Long term side effects of novel antipsychotics. Journal of Psychiatric Practice. 2000;6:299–309.
48. Casey, DE. Seroquel (quetiapine): preelinical and clinical findings of a new atypical antipsychotic. Exp Opin Invest Drugs. 1996;5:939–957.
49. Weiden, PJ. Quetiapine (Seroquel): a new “atypical” antipsychotic. J Pract Psych Behav Health. 1997:3:368–374.
50. Misra, LK, Erpenbach, JE, Hamlyn, H, et al. Quetiapine: a new atypical antipsychotic. S D J Med. 1998;51:189–193.
51. Beelan, AP, Yeo, KT, Lewis, LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperi-done. Hum Exp Toxicol. 2001;20:215–219.
52. Gajwani, P, Pozudo, L, Tesar, GE. QT interval prolongation associated with quetiapine (seroquel) overdose. Psychosomatics. 2000;41:63–65.
53. Seeger, TF, Seymour, PA, Schmidt, AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther. 1995,275:101–113.
54. Keck, P Jr, Buffenstein, A, Ferguson, J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4 week placebo-controlled trial. Psychopharmacology (Bed). 1998;140:173–184.
55. Daniel, DG, Zimbroff, DL, Potkin, SG, et al. Ziprasidone 80 and 160 mg/day in the acute exacerbation of schizophrenia and sehizoaffective disorder: a 6 week placebo-controlled trial. Neuropsychopharmacology. 1999;x20:491–505.
56. Geodon [package insert]. New York, NY: Pfizer Inc; 2001.
57. Goldman, LS. Medical illness in patients with schizophrenia. J Clin Psychiatry. 1999;60(suppl 21):10–15.
58. Gupta, S, Masand, PS, Kaplan, D, Bhandary, A. The relationship between schizophrenia and IBS. Schizophr Res 1997;23:265–268.
59. Brown, S, Birtwistle, J, Roe, L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697–701.
60. Dixon, L, Postrado, L, Delahanty, J, et al. The association of medical comorbidity in schizophrenia with poor physical and mental health. J New Ment Dis. 1999;187:496–502.
61. Pary, RJ, Barton, SN. Communication difficulty of patients with schizophrenia and physical illness. South Med J. 1988;81:489–490.
62. Tsuang, MT, Perkins, K, Simpson, JC. Physical diseases in schizophrenia and affective disorder. J Clin Psychiatry. 1983;44:42–46.
63. Brown, S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry. 1997;171:502–508.
64. Viewig, V, Levenson, J, Pandurangi, A, et al. Medical disorders in schizophrenic patients. Int J Psychiatry Med. 1995;25:137–142.
65. Suellen, M, Cutkendall, SM, Mo, J, Jones, JK, et al. Increased cardiovascular dis-ease in schizophrenia. Poster P-001-04 presented at: 7th World Congress of Biological Psychiatry; July 2001; Berlin, Germany.
66. Hennessy, S, Bilker, WB, Santanna, JC, et al. Cardiac arrest risk appears to vary little by choice of antipsychotic drug. Poster NR 507 presented at: Annual Meeting of the American Psychiatric Association; May 2001; New Orleans, LA.
67. Miceli, JJ, Smith, M, Robarge, L, et al. The effects of ketoconazole on ziprasidone pharmacokinetics-a placebo-controlled crossover study in healthy volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):71S–76S.
68. Ziprasidone. Bioltigical Therapies in Psychiatry. 2001;24:22. Study 128-054.